UBS analyst Michael Yee downgraded Ventyx Biosciences (VTYX) to Neutral from Buy with a price target of $14, down from $20, after the company entered into an agreement for Eli Lilly to acquire it for $14 per share. UBS expects the deal to close with limited regulatory risk.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences downgraded to Hold from Buy at Canaccord
- Ventyx downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating on Ventyx Biosciences Reflects Limited Upside Amid Eli Lilly All‑Cash Acquisition at $14 per Share
- Ventyx Biosciences downgraded to Hold from Buy at Clear Street
- Eli Lilly to Acquire Ventyx Biosciences in Cash Deal